Valion Bio (VBIO) Common Equity (2021 - 2026)
Valion Bio (VBIO) posted quarterly Common Equity of $16.8 million for Q4 2025, up 562.6% year-over-year from $2.5 million in Q4 2024, and up 392.0% quarter-over-quarter from $3.4 million in Q3 2025.
Valion Bio (VBIO) Common Equity (2021 - 2026) Analysis & Trends
Valion Bio's Common Equity history runs 5 years deep, the most recent figure standing at $16.8 million for Q4 2025.
- In Q4 2025, Common Equity rose 562.6% year-over-year to $16.8 million; the TTM figure through Dec 2025 stood at $16.8 million (up 562.6% YoY), while the FY2025 annual figure was $16.8 million, up 562.6% from the prior year.
- Common Equity for Q4 2025 stood at $16.8 million, up from $3.4 million in the prior quarter.
- The five-year high for Common Equity was $16.8 million in Q4 2025, with the low at -$5.8 million in Q3 2021.
- The 5-year median for Common Equity is $3.5 million (2023), against an average of $4.3 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 72.65% in 2022, then jumped 562.6% in 2025.
- Valion Bio's Common Equity stood at $13.3 million in 2021, then sank by 72.65% to $3.6 million in 2022, then declined by 1.38% to $3.6 million in 2023, then dropped by 29.19% to $2.5 million in 2024, then surged by 562.6% to $16.8 million in 2025.
- Business Quant data shows VBIO's Common Equity at $16.8 million in Q4 2025, $3.4 million in Q3 2025, and $3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 | 4.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.25 Mn |
| Dec 31, 2025 | 16.80 Mn |
| Sep 30, 2025 | 3.41 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 3.58 Mn |
| Sep 30, 2023 | 5.77 Mn |
| Jun 30, 2023 | 3.16 Mn |
| Mar 31, 2023 | 5.21 Mn |
| Dec 31, 2022 | 3.63 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 8.19 Mn |
| Mar 31, 2022 | 11.09 Mn |
| Dec 31, 2021 | 13.27 Mn |
| Sep 30, 2021 | -5.79 Mn |
| Jun 30, 2021 | -3.60 Mn |